NASDAQ:SGTX Sigilon Therapeutics (SGTX) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free SGTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$22.09▼$23.1050-Day Range$20.92▼$23.0652-Week Range$3.77▼$28.00Volume83,600 shsAverage Volume62,902 shsMarket Capitalization$56.40 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock Analysis Get Sigilon Therapeutics alerts: Email Address Sigilon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside6.5% Downside$21.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($12.65) to ($13.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.00 out of 5 starsMedical Sector907th out of 908 stocksPharmaceutical Preparations Industry423rd out of 424 stocks 1.0 Analyst's Opinion Consensus RatingSigilon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSigilon Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SGTX. Previous Next 0.0 Dividend Strength Dividend YieldSigilon Therapeutics does not currently pay a dividend.Dividend GrowthSigilon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGTX. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for SGTX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sigilon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Sigilon Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sigilon Therapeutics are expected to decrease in the coming year, from ($12.65) to ($13.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sigilon Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sigilon Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSigilon Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Sigilon Therapeutics Stock (NASDAQ:SGTX)Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. SGTX Stock News HeadlinesApril 14, 2024 | seekingalpha.comMCRB Seres Therapeutics, Inc.October 22, 2023 | wsj.comBeam Therapeutics Inc.April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.August 14, 2023 | markets.businessinsider.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 1, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.July 31, 2023 | msn.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 21, 2023 | businesswire.comSIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.July 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNMJuly 6, 2023 | msn.comCanaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy RecommendationJuly 6, 2023 | msn.comSigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28July 3, 2023 | msn.com5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for PismoJune 29, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. BuyoutJune 29, 2023 | finance.yahoo.comModerna Billionaire Set to Score 3,000% Gain on Tiny BiotechJune 29, 2023 | finanznachrichten.deEli Lilly and Company: Lilly to Acquire Sigilon TherapeuticsJune 29, 2023 | msn.comHealth Care Company Eli Lilly Announces Acquisition of Sigilon TherapeuticsJune 29, 2023 | bizjournals.comSigilon stock up 500% on Lilly acquisition newsJune 29, 2023 | finance.yahoo.comSigilon Therapeutics Shares Are Shooting Higher Today - What's Going OnJune 29, 2023 | msn.comSigilon stock skyrockets 650% on buyout deal with Eli LillyJune 29, 2023 | markets.businessinsider.comEli Lilly To Acquire Sigilon TherapeuticsJune 29, 2023 | msn.comWhy Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?June 29, 2023 | technews.tmcnet.comSGTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sigilon Therapeutics, Inc. Is Fair to ShareholdersJune 29, 2023 | finance.yahoo.comLilly to Acquire Sigilon TherapeuticsJune 29, 2023 | finance.yahoo.comEli Lilly to buy Sigilon Therapeutics to expand diabetes treatmentsMay 26, 2023 | markets.businessinsider.comMorgan Stanley Sticks to Their Hold Rating for Sigilon Therapeutics (SGTX)May 25, 2023 | msn.comMorgan Stanley Maintains Sigilon Therapeutics (SGTX) Equal-Weight RecommendationSee More Headlines Receive SGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SGTX CUSIPN/A CIK1821323 Websigilon.com Phone617-336-7540FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside-6.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($12.2328) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net Margins-171.29% Pretax Margin-171.29% Return on Equity-83.07% Return on Assets-38.17% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$12.94 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value$15.68 per share Price / Book1.43Miscellaneous Outstanding Shares2,510,000Free Float2,351,000Market Cap$56.40 million OptionableNot Optionable Beta4.12 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Rogerio Vivaldi Coelho M.B.A. (Age 59)M.D., MBA, Pres, CEO & Director Comp: $924.67kMr. Philip Ashton-Rickardt Ph.D. (Age 59)Chief Scientific Officer Comp: $614.08kDr. Robert S. Langer Jr. (Age 74)Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board Dr. Daniel G. Anderson Ph.D. (Age 53)Co-Founder & Member of Scientific Advisory Board Dr. Omid Veiseh Ph.D.Co-FounderDr. José Oberholzer M.D.Co-FounderDr. Arturo Vegas Ph.D.Co-FounderMr. Josias Fantato De Pontes M.B.A. (Age 56)CFO, Principal Accounting Officer & Treasurer Mr. Bernd Kullmann M.B.A.Sr. VP and Head of Operations & Project ManagementMr. Matthew P. Kowalsky J.D. (Age 50)Chief of Staff, Chief Legal and Admin. Officer & Sec. More ExecutivesKey CompetitorsReneo PharmaceuticalsNASDAQ:RPHMKronos BioNASDAQ:KRONGain TherapeuticsNASDAQ:GANXHomology MedicinesNASDAQ:FIXXSCYNEXISNASDAQ:SCYXView All CompetitorsInsidersLilly & Co EliBought 1,718,493 shares on 8/11/2023Total: $25.64 M ($14.92/share) SGTX Stock Analysis - Frequently Asked Questions Should I buy or sell Sigilon Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares. View SGTX analyst ratings or view top-rated stocks. What is Sigilon Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for Sigilon Therapeutics' stock. Their SGTX share price targets range from $21.00 to $21.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests that the stock has a possible downside of 6.5%. View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts. How were Sigilon Therapeutics' earnings last quarter? Sigilon Therapeutics, Inc. (NASDAQ:SGTX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($8.19) EPS for the quarter, topping analysts' consensus estimates of ($8.58) by $0.39. The firm had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%. When did Sigilon Therapeutics' stock split? Sigilon Therapeutics's stock reverse split on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Sigilon Therapeutics IPO? Sigilon Therapeutics (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity served as the underwriters for the IPO. This page (NASDAQ:SGTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigilon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
